Peptide Policy Watch

Everyone in the gym is talking about peptides. Here's what the research actually says

By · Published

Illustration of a microscope, two empty flasks, a stack of papers and a three-step staircase of coloured blocks, with a floating bead-chain molecule.
Illustration (AI-generated): Evidence: microscope, flasks, papers and a three-step staircase of blocks. Image credits

One 2025 systematic review of BPC-157, a peptide often name-checked in fitness circles, found 544 articles. After duplicates were removed, 36 studies were included. Thirty-five were preclinical. One involved people.

Published October 25, 2026. Status is "as of" this date. Sources and retrieval dates are at the bottom. This is not medical advice. The site owner is not a medical professional. Nothing here is a recommendation to use any substance.

The short version

  • "The research" can mean very different things: cells in a dish, animals, a handful of people, or large human trials. They are not equal. [V]
  • In the 2025 review, 35 of the 36 included BPC-157 studies were preclinical, and its authors wrote "No clinical safety data were found." [V]
  • The one clinical study was a chart review at a single clinic that used no standard tools to measure function. Its authors called for future studies. [V]
  • This does not say a peptide works or fails. It says where the evidence sits today. [V]

A ladder, not a verdict

When someone says "the research shows," ask which rung of the ladder they mean. Here is a simple version, built from how FDA describes drug development:

  1. Cells in a lab (in vitro). Fast and cheap. FDA describes this as part of preclinical research.
  2. Animals (in vivo). Also preclinical. FDA says its purpose is to learn whether a drug "has the potential to cause serious harm" before it is tested in people.
  3. Small human reports. Case reports and chart reviews. They can raise questions, but they are not designed to answer them.
  4. Controlled human trials (Phases 1 to 3). FDA describes Phase 1 as 20 to 100 people, Phase 2 as up to several hundred, and Phase 3 as 300 to 3,000.
  5. Approval and monitoring. After approval, FDA says Phase 4 trials are carried out once a drug has been approved, during post-market safety monitoring.

Sources: FDA's Step 2 and Step 3 drug-development pages. [V]

Each rung up answers different questions. FDA says preclinical research "is not a substitute for studies" of how a drug interacts with the human body.

The attrition rate is the surprise

Even drugs that earn their way into human trials mostly do not go on to approval. FDA's page says that approximately 70% of drugs move from Phase 1 to the next phase, approximately 33% from Phase 2, and approximately 25-30% from Phase 3. [V]

That is FDA's own rough description of drugs that were already carefully chosen for human testing. It is a good reminder that an early result, however exciting, is a starting point.

What the BPC-157 review found

The HSS Journal review (Vasireddi and colleagues, 2025) searched PubMed, Cochrane and Embase from each database's start to June 3, 2024. The abstract reports:

  • 544 articles identified, 36 studies included: 35 preclinical studies and 1 clinical study.
  • The authors describe the body of work as "level IV and level V studies." [V]
  • "No clinical safety data were found." [V]
  • Their conclusion says the evidence "suggests that BPC-157 shows promise for promoting recovery from musculoskeletal injuries," and that adverse effects are possible "due to unregulated manufacturing, contamination, or unknown clinical safety." [V]

Read that second-to-last point carefully. "Shows promise" is the authors' reading of mostly animal and cell work. It is not a finding that anything works in people, and the same abstract says it found no clinical safety data.

The one human study, and its limits

The single clinical study is a 2021 paper in Alternative Therapies in Health and Medicine (Lee and Padgett). Here is only its design:

  • A retrospective chart review at one clinic, covering a one-year window (2019 to 2020). Follow-up varied from patient to patient.
  • 17 patients; 16 were reached by phone. Patients were asked to rate their own pain and how much it helped.
  • The paper states that "No specific tools were used to measure" improvement in function, quality of life, stiffness or activities of daily living.
  • The authors say future studies are needed.

A small review of charts at one clinic cannot show what would have happened without the treatment, and the abstract describes no untreated comparison group. We are not repeating the study's results here, because a design like this cannot support conclusions about whether something works.

One more lesson hides in the two abstracts. The review and the original study describe the same group's results in different terms: one counts relief lasting more than six months, the other counts "significant improvement." A headline number depends on what was measured, and how. [V]

Why you should care

The conversation about peptides in gyms and wellness circles often skips the question of evidence type. A friend's story, a podcast, a clinic's website and a randomized trial can all be called "research." They are not the same thing.

Knowing the rungs lets you read a claim faster and more calmly. It is not about being cynical. A claim at rung 1 or 2 can be interesting and still be far from telling anyone what happens in people.

What to do with this

Questions to carry into your own reading or a clinician visit:

  1. Which rung is this claim on? Cells, animals, case reports or controlled human trials?
  2. Is there a comparison group? What happened to people who did not get the treatment?
  3. What were they measuring, and how? Self-reported ratings or standard tools?
  4. Is there any human safety information? The review says that for BPC-157 it found none in clinical studies.
  5. Is this an approved medicine, or a product with no approval for human use? See peptides in plain English.

None of this tells you what to do. A clinician who knows your history can talk about what applies to you.

What to watch next

  • Sport: the World Anti-Doping Agency's 2026 list names several peptides. See peptides and the WADA list.
  • Regulators: FDA's advisory committee met on seven peptides in July 2026. Our timeline tracks what is final and what is pending.
  • Coming: how to read a clinical-trial listing, and a "Myth vs. evidence" series.

Sources (all retrieved October 25, 2026)

  1. Vasireddi N, Hahamyan H, Salata MJ, et al., "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review," HSS Journal 21(4):485-495, 2025 [V, abstract] — https://pubmed.ncbi.nlm.nih.gov/40756949/
  2. Lee E, Padgett B, "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain," Alternative Therapies in Health and Medicine 27(4):8-13, 2021 [V, abstract] — https://pubmed.ncbi.nlm.nih.gov/34324435/
  3. FDA, "Step 2: Preclinical Research," content current as of 01/04/2018 [V] — https://www.fda.gov/patients/drug-development-process/step-2-preclinical-research
  4. FDA, "Step 3: Clinical Research," content current as of 01/04/2018 [V] — https://www.fda.gov/patients/drug-development-process/step-3-clinical-research

Reading this for health reasons? This site reports on regulation; it is not medical advice. See our disclaimer, how we source and corrections policy.